Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of trigonin a in the preparation of anti-ischemic stroke medicine

A technology for ischemic stroke and cerebral apoplexy, which is applied in the field of medicine, can solve the problem of the lack of anti-ischemic stroke effect of the three-lens component in three-lens, and achieve the protection of neuron cells, reduce the size of cerebral infarction and cerebral infarction. Exponential, wide-source effects

Active Publication Date: 2021-08-27
GUANGDONG PHARMA UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there is no research report on whether the three-lens component in the three-lens has an anti-ischemic stroke effect. To study whether the three-lens component in the three-lens has an anti-ischemic stroke effect can make up for the gap in the prior art, and It is of great significance to guide the development of clinical medication and new drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trigonin a in the preparation of anti-ischemic stroke medicine
  • Application of trigonin a in the preparation of anti-ischemic stroke medicine
  • Application of trigonin a in the preparation of anti-ischemic stroke medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Inhibitory effect of trigonin A on calcium ion overload injury and hypoxia and glucose deficiency injury in PC12 cells

[0030] 1. Experimental materials

[0031] (1) Experimental cells

[0032] PC12 cell line (rat adrenal chromaffin tumor cells) was purchased from Shanghai Cell Resource Center.

[0033] (2) Experimental reagents

[0034]

[0035] (3) Experimental equipment

[0036]

[0037]

[0038] 2. The effect of trigonin A on PC12 cell calcium overload injury model

[0039] 1. Effect of different concentrations of KCl on the survival rate of PC12 cells

[0040] (1) Experimental method

[0041] Based on the method established by KCl-induced calcium ion overload injury model of PC12 cells, and improved, the specific operation steps are as follows:

[0042] Take PC12 cells out of the incubator, add trypsin to digest, stop the digestion after the cells fall off, centrifuge, add serum-containing medium to make a suspension, add 100 μL to each we...

Embodiment 2

[0083] Example 2 Pharmacodynamic experiment of trigonin A on cerebral ischemia-reperfusion injury in rats

[0084] 1. Experimental materials

[0085] (1) Experimental animals

[0086] SPF grade SD rats (male, body weight 250-300 g), the experimental rats were provided by the Guangdong Medical Experimental Animal Center, license number: SCXK (Guangdong) 2013-0002. They were bred by the Experimental Animal Center of Guangdong Pharmaceutical University.

[0087] (2) Experimental equipment

[0088]

[0089]

[0090] (3) Experimental reagents

[0091]

[0092]

[0093] 2. Experimental method and experimental results of the efficacy of trigonin A on cerebral ischemia-reperfusion injury in rats

[0094] 1. Grouping and administration of experimental animals

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of trigonin A in the preparation of anti-ischemic stroke medicine. Specifically, the present invention has found that trigonin A has a significant inhibitory effect on calcium ion overload injury and hypoxia and glucose deficiency injury, can improve the symptoms of neurological deficits, and significantly reduce the cerebral infarct size and Brain index; significantly reduce serum TAX2, ET-1, TNFα, IL-β, MDA levels and LDH activity, and at the same time improve the blood-brain barrier and protect neuron cells. It is used for the treatment of ischemic stroke, The curative effect is remarkable, and the dosage is small. In addition, Sanlenin A is the active ingredient of the traditional Chinese medicine Sanleng. It has a wide range of sources, is safe and low-toxic, and provides a new choice and a strong basis for the development of natural medicines against ischemic stroke. It has broad development space and good application prospects.

Description

technical field [0001] The invention belongs to the technical field of medicine. More specifically, it relates to the application of trigonin A in the preparation of anti-ischemic stroke medicine. Background technique [0002] Ischemic stroke (Stroke) is a general term for brain tissue necrosis caused by stenosis or occlusion of cerebral blood supply arteries (carotid artery and vertebral artery) and insufficient cerebral blood supply. Cerebral ischemia includes four types, divided into transient ischemic attack (TIA), reversible neurological deficit (RIND), progressive stroke (SIE) and complete stroke (CS). TIA has no cerebral infarction, but RIND, SIE and CS have different degrees of cerebral infarction. At present, the methods for treating ischemic stroke are mainly taking chemical drugs or surgical treatment. The prognosis of the disease is poor, there is a certain rate of disability and death, and recurrent attacks can occur; in addition, chemical drugs have strong to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4965A61P9/10
CPCA61K31/4965A61P9/10
Inventor 梁生旺宋伟群王淑美贤明华许晓丽薛琪
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com